Trial Profile
The efficacy of the administration of SGLT-2 inhibitor and/or DPP-4 inhibitor in type 2 diabetic patient with basal-bolus insulin therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 May 2016 New trial record